Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 196-206

  Busby, Robert W ^a   Kessler, Marco M ^a   Bartolini, Wilmin P ^a   Bryant, Alexander P ^a   Hannig, Gerhard ^a   Higgins, Carolyn S ^a   Solinga, Robert M ^a   Tobin, Jenny V ^a   Wakefield, James D ^a   Kurtz, Caroline B ^a   Currie, Mark G ^a  

^a IRONWOOD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR RECEPTOR; CYCLIC GMP; CYSTEINYLCYSTEINYLGLUTAMYLTYROSYLCYSTEINYLCYSTEINYLASPARAGINYLPROLYLALANYLCYSTEINYLTHREONYLGLYCYLCYSTEINE; DRUG METABOLITE; GUANYLATE CYCLASE ACTIVATOR; LINACLOTIDE; MM 419447; MM 421202; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CHRONIC IDIOPATHIC CONSTIPATION; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISULFIDE BOND; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG FECES LEVEL; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INTESTINAL SECRETION; IRRITABLE COLON; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALKYLATION; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CONSTIPATION; CYCLIC AMP; FECES; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINES; IRRITABLE BOWEL SYNDROME; MALE; PEPTIDE HYDROLASES; PEPTIDES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84871682733     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199430     Document Type: Article

References (39)

1. Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx- Orenstein A, Kurtz CB, Sharma V, and Johnston JM, et al. (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133:761-768. (Pubitemid 47374145)
2. Zahedi Avval F and Holmgren A (2009) Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for Mammalian s phase ribonucleotide reductase. J Biol Chem 284:8233-8240.
3. Bauer CW and Miskinis AM (1947) The carboxypeptidase activity of pancreatin U.S. P. J Am Pharm Assoc Am Pharm Assoc 36:123-126.
4. Brandwein H, Deutsch A, Thompson M, and Giannella RA (1985) Production of neutralizing monoclonal antibodies to Escherichia coli heat-stable enterotoxin. Infect Immun 47:242-246. (Pubitemid 15194617)
5. Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, and Mahajan-Miklos S, et al. (2010) Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 86:760-765.
6. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Mahajan-Miklos S, Pierce CM, Solinga RM, and Sun LJ, et al. (2010) Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 649: 328- 335.
7. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, Macdougall JE, Jia XD, Shao JZ, and Fitch DA, et al. (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol DOI:10.1038/ajg.2012.254 [published ahead of print].
8. Currie MG, Fok KF, Kato J, Moore RJ, Hamra FK, Duffin KL, and Smith CE (1992) Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA 89:947-951.
9. Dahm LJ and Jones DP (2000) Rat jejunum controls luminal thiol-disulfide redox. J Nutr 130:2739-2745.
10. Daniel H (2004) Molecular and integrative physiology of intestinal peptide transport. Annu Rev Physiol 66:361-384.
11. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M, Bryant AP, and Kurtz C, et al. (2010) Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 22:312-e84.
12. Fan X, Hamra FK, Freeman RH, Eber SL, Krause WJ, Lim RW, Pace VM, Currie MG, and Forte LR (1996) Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. Biochem Biophys Res Commun 219:457-462. (Pubitemid 26090909)
13. Fernandes AP and Holmgren A (2004) Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid Redox Signal 6:63-74. (Pubitemid 38063976)
14. Fondacaro JD, Kolpak DC, Burnham DB, and McCafferty GP (1990) Cecectomized rat. A model of experimental secretory diarrhea in conscious animals. J Pharmacol Methods 24:59-71. (Pubitemid 20279896)
15. Forte LR, Jr (2004) Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 104:137-162.
16. Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, Chin DT, Tompkins JA, Fok KF, and Smith CE, et al. (1993) Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA 90:10464-10468. (Pubitemid 23347062)
17. Hamra FK, Fan X, Krause WJ, Freeman RH, Chin DT, Smith CE, Currie MG, and Forte LR (1996) Prouroguanylin and proguanylin: purification from colon, structure, and modulation of bioactivity by proteases. Endocrinology 137: 257- 265.
18. Hamra FK, Eber SL, Chin DT, Currie MG, and Forte LR (1997) Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity. Proc Natl Acad Sci USA 94:2705-2710. (Pubitemid 27136940)
19. Johnson LR, Alpers DH, Christensen J, and Jacobson ED, editors (1994) Physiology of the Gastrointestinal Tract, Raven Press, New York.
20. Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, and Lembo AJ (2010) Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 139:1877-1886, e2.
21. Kim YS, Birtwhistle W, and Kim YM (1972) Peptide hydrolases in the brush border and soluble fractions of small intestinal mucosa of rat and man. J Clin Invest 51: 1419-1430.
22. Krause WJ, Cullingford GL, Freeman RH, Eber SL, Richardson KC, Folk KF, Currie MG, and Forte LR (1994) Distribution of heat-stable enterotoxin/ guanylin receptors in the intestinal tract of man and other mammals. J Anat 184: 407-417. (Pubitemid 24114601)
23. Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, and Johnston JM (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138:886-895, e1.
24. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Shao JZ, Lavins BJ, Currie MG, and Fitch DA, et al. (2011) Two randomized trials of linaclotide for chronic constipation. N Engl J Med 365:527-536.
25. London RM, Krause WJ, Fan X, Eber SL, and Forte LR (1997) Signal transduction pathways via guanylin and uroguanylin in stomach and intestine. Am J Physiol 273:G93-G10.
26. Mayer EA, Bradesi S, Chang L, Spiegel BMR, Bueller JA, and Naliboff BD (2008) Functional GI disorders: from animal models to drug development. Gut 57:384-404. (Pubitemid 351288106)
27. Qian X, Prabhakar S, Nandi A, Visweswariah SS, and Goy MF (2000) Expression of GC-C, a receptor-guanylate cyclase, and its endogenous ligands uroguanylin and guanylin along the rostrocaudal axis of the intestine. Endocrinology 141: 3210-3224. (Pubitemid 32269009)
28. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, and Eng P, et al. (2012) A 12-week, randomized, controlled trial with a 4- week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol DOI: 10.1038/ ajg.2012.255 [published ahead of print].
29. Roque MV and Camilleri M (2011) Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol 5:301-310.
30. Sanderink GJ, Artur Y, and Siest G (1988) Human aminopeptidases: a review of the literature. J Clin Chem Clin Biochem 26:795-807. (Pubitemid 19028706)
31. Schulz S, Green CK, Yuen PST, and Garbers DL (1990) Guanylyl cyclase is a heatstable enterotoxin receptor. Cell 63:941-948. (Pubitemid 120034935)
32. Silk DBA, Grimble GK, and Rees RG (1985) Protein digestion and amino acid and peptide absorption. Proc Nutr Soc 44:63-72.
33. Thiagarajah JR, Broadbent T, Hsieh E, and Verkman AS (2004) Prevention of toxininduced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 126:511-519. (Pubitemid 38182308)
34. 18Tyr Escherichia coli heat-stable enterotoxin species purified by high-performance liquid chromatography. Anal Biochem 148:26-36.
35. Wensel TM and Luthin DR (2011) Linaclotide: a novel approach to the treatment of irritable bowel syndrome. Ann Pharmacother 45:1535-1543.
36. Wiegand RC, Kato J, and Currie MG (1992) Rat guanylin cDNA: characterization of the precursor of an endogenous activator of intestinal guanylate cyclase. Biochem Biophys Res Commun 185:812-817.
37. Wilkinson GR (1997) The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev 27:129-159.
38. Woodley JF (1994) Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 11:61-95.
39. Yu Y, Jawa A, Pan W, and Kastin AJ (2004) Effects of peptides, with emphasis on feeding, pain, and behavior: a 5-year (1999-2003) review of publications in Peptides. Peptides 25:2257-2289. (Pubitemid 39574464)